The results have shown that it is possible to detect HER2 amplification in cfDNA of some patients on follow-up following primary breast cancer treatment despite the fact that they had no evidence of metastatic disease, either at the time of sampling or >6 years after. This evidence concerns the gene ERBB2 and breast carcinoma.